Jean-Francois Groulx

Dr. Jean-Francois Groulx


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2012 in Autophagy
Verified
Journal Article
Closed access
PDF file
JGJean-Francois Groulx
Jean-Francois Groulx
TKTaoufik Khalfaoui
Taoufik Khalfaoui
Yannick D. BenoitYannick D. Benoit
Yannick D. Benoit
GBGérald Bernatchez
Gérald Bernatchez
JCJulie C. Carrier
Julie C. Carrier
JBJean-François Beaulieu
Jean-François Beaulieu
Recently, autophagy has been found to be strongly activated in colon cancer cells, but few studies have addressed the normal colon mucosa. The aim of this study was to characterize autophagy in normal human intestinal cells. We used the expression of LC3-II and BECN1 as well as SQSTM1 as markers of autophagy activity. Using the normal human intestinal epithelial crypt (HIEC) cell experimental model, we found that autophagy was much more active in undifferentiated cells than in differentiated cells. In the normal adult colonic mucosa, BECN1 was found in the proliferative epithelial cells of the lower part of the gland while SQSTM1 was predominantly found in the differentiated cells of the upper part of the gland and surface epithelium. Interestingly, the weak punctate pattern of SQSTM1 expression in the lower gland colocalized with BECN1-labeled autophagosomes. The usefulness of SQSTM1 as an active autophagy marker was confirmed in colon cancer specimens at the protein and transcript levels. In conclusion, our results show that autophagy is active in the colonic gland and is associated with the intestinal proliferative/undifferentiated and progenitor cell populations.

9 July 2009 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ADAnders Bondo Dydensborg
Anders Bondo Dydensborg
ITInga C Teller
Inga C Teller
JGJean-Francois Groulx
Jean-Francois Groulx
NBNuria Basora
Nuria Basora
FPFréderic Paré
Fréderic Paré
JBJean-François Beaulieu
Jean-François Beaulieu
Background: Integrins are known to be important contributors to cancer progression. We have previously shown that the integrin β4 subunit is up-regulated in primary colon cancer. Its partner, the integrin α6 subunit, exists as two different mRNA splice variants, α6A and α6B, that differ in their cytoplasmic domains but evidence for distinct biological functions of these α6 splice variants is still lacking.Methods: In this work, we first analyzed the expression of integrin α6A and α6B at the protein and transcript levels in normal human colonic cells as well as colorectal adenocarcinoma cells from both primary tumors and established cell lines. Then, using forced expression experiments, we investigated the effect of α6A and α6B on the regulation of cell proliferation in a colon cancer cell line.Results: Using variant-specific antibodies, we observed that α6A and α6B are differentially expressed both within the normal adult colonic epithelium and between normal and diseased colonic tissues. Proliferative cells located in the lower half of the glands were found to predominantly express α6A, while the differentiated and quiescent colonocytes in the upper half of the glands and surface epithelium expressed α6B. A relative decrease of α6B expression was also identified in primary colon tumors and adenocarcinoma cell lines suggesting that the α6A/α6B ratios may be linked to the proliferative status of colonic cells. Additional studies in colon cancer cells showed that experimentally restoring the α6A/α6B balance in favor of α6B caused a decrease in cellular S-phase entry and repressed the activity of c-Myc.Conclusion: The findings that the α6Bβ4 integrin is expressed in quiescent normal colonic cells and is significantly down-regulated in colon cancer cells relative to its α6Aβ4 counterpart are consistent with the anti-proliferative influence and inhibitory effect on c-Myc activity identified for this α6Bβ4 integrin. Taken together, these findings point out the importance of integrin variant expression in colon cancer cell biology.

3 February 2018 in Cancers
Verified
Journal Article
Open access
PDF file
JGJean-Francois Groulx
Jean-Francois Groulx
SBSalah Boudjadi
Salah Boudjadi
JBJean-François Beaulieu
Jean-François Beaulieu
The α6 integrin subunit (ITGA6) pre-mRNA undergoes alternative splicing to form two splicing variants, named ITGA6A and ITGA6B. In primary human colorectal cancer cells, the levels of both ITGA6 and β4 integrin subunit (ITGB4) subunits of the α6β4 integrin are increased. We previously found that the upregulation of ITGA6 is a direct consequence of the increase of the pro-proliferative ITGA6A variant. However, the mechanisms that control ITGA6 expression and splicing into the ITGA6A variant over ITGA6B in colorectal cancer cells remain poorly understood. Here, we show that the promoter activity of the ITGA6 gene is regulated by MYC. Pharmacological inhibition of MYC activity with the MYC inhibitor (MYCi) 10058-F4 or knockdown of MYC expression by short hairpin RNA (shRNA) both lead to a decrease in ITGA6 and ITGA6A levels in colorectal cancer cells, while overexpression of MYC enhances ITGA6 promoter activity. We also found that MYC inhibition decreases the epithelial splicing regulatory protein 2 (ESRP2) splicing factor at both the mRNA and protein levels. Chromatin immunoprecipitation revealed that the proximal promoter sequences of ITGA6 and ESRP2 were occupied by MYC and actively transcribed in colorectal cancer cells. Furthermore, expression studies in primary colorectal tumors and corresponding resection margins confirmed that the up-regulation of the ITGA6A subunit can be correlated with the increase in MYC and ESRP2. Taken together, our results demonstrate that the proto-oncogene MYC can regulate the promoter activation and splicing of the ITGA6 integrin gene through ESRP2 to favor the production of the pro-proliferative ITGA6A variant in colorectal cancer cells.

1 May 2011 in Gastroenterology
Verified
Journal Article
Closed access
JGJean-Francois Groulx
Jean-Francois Groulx
JBJean-François Beaulieu
Jean-François Beaulieu

31 May 2009 in Gastroenterology
Verified
Journal Article
Closed access
JGJean-Francois Groulx
Jean-Francois Groulx
DMDenis Martel
Denis Martel
EHElizabeth Herring
Elizabeth Herring
JBJean-François Beaulieu
Jean-François Beaulieu

1 May 2013 in Gastroenterology
Verified
Journal Article
Closed access
JGJean-Francois Groulx
Jean-Francois Groulx
VGVéronique Giroux
Véronique Giroux
EHElizabeth Herring
Elizabeth Herring
NBNuria Basora
Nuria Basora
JCJulie Carrier
Julie Carrier
JBJean-François Beaulieu
Jean-François Beaulieu